Andersen Pharma Polandsp. z o.o.
Research and experimental development on biotechnology
KRS: NIP: REGON:
Overview
Status
Active
Registry date
2018-04-20
Share capital
100 000,00 PLN
Registered address
ul. Domaniewska 47/10, 02-672 Warszawa, Poland
Financials
Revenue history (in k)
Filing timeliness
Financial statements were filed on time, on average 106 days early.
- 202502/04/2026
- 202419/03/2025
- 202312/03/2024
- 202226/04/2023
- 202108/06/2022
- 202029/04/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 135.22kMedianUSD 55.24kAverageUSD 2.71m
Net profit
This companyUSD -10.02kMedianUSD -1.27kAverageUSD -91.85k
Operating costs
This companyUSD 125.40kMedianUSD 65.85kAverageUSD 2.66m
Assets
This companyUSD 165.28kMedianUSD 133.19kAverageUSD 3.03m
Industry
Authorized Representatives
Marcus Clarke – Management Board Member
Deepak Kumar Murpani – Management Board Member
Manner of representation
Each member of the management board is entitled to make declarations independently on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Andersen Pharma Australia Limited | 750 | $20,259.32 | 75% |
Deepak Kumar Murpaniage 54 | 250 | $6,753.11 | 25% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2018-08-02.
No bank accounts reported to the VAT Taxpayer Register.
Debt
No entries in the National Debtors Register (KRZ).
Public aid
4 public aid cases recorded, with a total value of $8,410.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,794$1,794 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Sep 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,732$1,732 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Jun 10, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $3,077$3,077 | Polski Fundusz Rozwoju S.A. |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Frontline BiosciencesS.A. | $219,186.29 | frontlinebiosciences.com | ||
| AI Corelabsp. z o.o. | $128,365.55 | aicorelab.com | ||
| ModicaP.S.A. | $103,400.72 | modica.bio | ||
| WPD Pharmaceuticalssp. z o.o. | $90,822.78 | wpdpharmaceuticals.com | ||
| WPD PharmaceuticalsS.A. | $87,561.70 | wpdpharmaceuticals.pl | ||
| Stenocoatsp. z o.o. | $36,665.21 | stenocoat.com | ||
| Platforma Badań Genetycznychsp. z o.o. | $28,558.39 | zdrowegeny.pl | ||
| Bioselsp. z o.o. | $19,100.32 | selol.pl | ||
| Omnisepticasp. z o.o. | $3,475.29 | omniseptica.com | ||
| Wavex Energysp. z o.o. | $142.33 | wavexenergy.com |
Change history
| Date | Event | |
|---|---|---|
| 2018-10-10 | Share capital change (5,000.00 PLN → 100,000.00 PLN) | |
| 2018-04-20 | Entered in the register |
FAQ
Last updated: 2026-04-03